Joshua Yang

Joshua Yang is a biotechnology entrepreneur and the Co-Founder and CEO of Glyphic Biotechnologies, a seed-stage biotech startup developing next-generation protein sequencing technology.12 Here are some key details about Joshua Yang:

Professional Background

Joshua Yang has founded multiple biotech companies:

• Co-founder and CEO of Glyphic Biotechnologies
• Co-founder of Nephrosant, a Series A-stage diagnostics biotech startup focused on non-invasive kidney disease diagnostics1

Education

Joshua Yang has an extensive educational background in medicine and business:

• MBA from Stanford Graduate School of Business, where he graduated as the Henry Ford II Scholar (Valedictorian) and an Arjay Miller Scholar (Top 10%)1
• MD-PhD candidate at Johns Hopkins University School of Medicine and Department of Biomedical Engineering
• M.Eng. in Translational Medicine from UC San Francisco and UC Berkeley
• B.S. in Bioengineering: Biotechnology and B.S. in General Biology from UC San Diego1

Achievements and Recognition

• Named in Forbes 30 Under 30 Healthcare list in 20211
• Recipient of Biocom California's Life Science Catalyst Award in 20211
• Winner of multiple awards and competitions, including 1st place at the Merck Innovation Cup 20201

Research and Publications

Joshua Yang has contributed to scientific research, with publications in journals such as Science Translational Medicine. His work focuses on areas like kidney disease diagnostics and biotechnology innovations.1

Social Media and Contact

• LinkedIn: @joshuayoungyang2
• Twitter: @joshuayoungyang1
• Email: me@joshuayang.com1

Joshua Yang's career demonstrates a strong commitment to innovation in biotechnology, particularly in the areas of protein sequencing and medical diagnostics.